# DGKG

## Overview
DGKG is a gene that encodes the enzyme diacylglycerol kinase gamma, a member of the kinase family involved in lipid signaling pathways. This enzyme plays a pivotal role in cellular signaling by catalyzing the conversion of diacylglycerol (DAG) to phosphatidic acid (PA), both of which are critical lipid second messengers. The activity of diacylglycerol kinase gamma is essential for modulating various signaling pathways, including those involving protein kinase C (PKC), protein kinase D (PKD), and the RAS and mTOR pathways, which are crucial for regulating cell proliferation, apoptosis, and metabolism (TaniguchiPonciano2024Longitudinal). The enzyme is primarily localized in the cytoplasm and plasma membrane, where it influences cellular processes such as growth, differentiation, and apoptosis. DGKG's interactions with other proteins, such as PKC and RasGRP, further underscore its role in maintaining cellular homeostasis and its potential impact on various signaling pathways. Alterations in DGKG expression have been linked to several diseases, including acute myeloid leukemia, pituitary neuroendocrine tumors, and dilated cardiomyopathy, highlighting its clinical significance (Gravina2023Role; Xu2022Screening).

## Structure
The DGKG protein is characterized by several conserved domains essential for its function in lipid signaling pathways. It contains a DAG kinase catalytic domain, which is crucial for the conversion of diacylglycerol (DAG) to phosphatidic acid. This catalytic domain is a defining feature of the enzyme, facilitating its primary biochemical activity. Additionally, DGKG includes accessory domains such as EF-hand motifs, which are typically involved in calcium binding and may play a role in the regulation of the enzyme's activity.

Post-translational modifications of DGKG can include phosphorylation, which may influence the enzyme's activity, stability, or interaction with other cellular components. These modifications are common in signaling proteins and can modulate their function in response to cellular signals.

DGKG is also subject to alternative splicing, resulting in different isoforms that may have distinct functions or regulatory properties. These splice variants allow the protein to participate in a variety of cellular contexts and signaling pathways, potentially expanding its functional repertoire. The presence of multiple isoforms underscores the complexity of DGKG's role in cellular signaling and its adaptability to different physiological conditions.

## Function
DGKG (diacylglycerol kinase gamma) is an enzyme that plays a crucial role in lipid signaling by catalyzing the phosphorylation of diacylglycerol (DAG) to produce phosphatidic acid (PA). Both DAG and PA are important lipid second messengers involved in various cellular processes. This enzymatic activity is significant in modulating signaling pathways such as those involving protein kinase C (PKC), protein kinase D (PKD), RAS, and mTOR, which are essential for regulating cell proliferation, apoptosis, and metabolism (TaniguchiPonciano2024Longitudinal).

DGKG is primarily active in the cytoplasm and plasma membrane, where it influences pathways related to cell growth, differentiation, and apoptosis. Its regulation of DAG and PA levels can impact signaling pathways like RHOA, NFKB, and MAPK1, which are involved in cell proliferation and other cellular functions (TaniguchiPonciano2024Longitudinal). In healthy human cells, DGKG likely participates in similar signaling and metabolic processes, contributing to the regulation of glucose and lipid metabolism, cytoskeleton rearrangement, and granule maturation and secretion (TaniguchiPonciano2024Longitudinal). The enzyme's activity is crucial for maintaining cellular homeostasis and responding to various physiological stimuli.

## Clinical Significance
Alterations in the expression of the DGKG gene have been implicated in several diseases. In acute myeloid leukemia (AML), DGKG is significantly overexpressed compared to normal bone marrow, and its high expression is associated with a more favorable prognosis, suggesting a complex role in AML pathogenesis (Gravina2023Role). However, another study indicates that high DGKG expression is inversely correlated with prolonged survival, highlighting the gene's potential impact on patient outcomes (Gravina2023Role).

In pituitary neuroendocrine tumors (PitNET), DGKG is upregulated and involved in metabolic pathways such as phosphatidylinositol signaling and phospholipase D signaling. This upregulation suggests a role in tumor biology, with potential therapeutic implications, as certain FDA-approved drugs could be repurposed to target DGKG (TaniguchiPonciano2024Longitudinal).

DGKG is also upregulated in dilated cardiomyopathy (DCM), where it is associated with lipid metabolism disorders that may exacerbate heart dysfunction. Its expression is positively correlated with age, indicating its potential as a diagnostic marker for DCM (Xu2022Screening). In cardiovascular diseases, DGKG is identified as a hub gene in a network related to cell adhesion, with implications for conditions like hypertension and cardiac remodeling (Schiano2022De).

## Interactions
DGKG (diacylglycerol kinase gamma) is known to participate in various protein interactions that are crucial for its role in lipid signaling pathways. It interacts with protein kinase C (PKC), a family of protein kinases involved in controlling the function of other proteins through the phosphorylation of hydroxyl groups of serine and threonine amino acid residues. This interaction is significant as PKC is a key player in signal transduction pathways that regulate cellular processes such as proliferation and differentiation. DGKG's interaction with PKC suggests a role in modulating these pathways by converting diacylglycerol (DAG) to phosphatidic acid (PA), thereby influencing the availability of DAG, a known activator of PKC.

Additionally, DGKG interacts with RasGRP, a guanine nucleotide exchange factor that activates the Ras signaling pathway. This interaction indicates that DGKG may influence Ras-mediated signaling, which is critical for cell growth and differentiation. The involvement of DGKG in multiprotein complexes further suggests that its activity and function are modulated through these interactions, allowing it to participate in a broader range of cellular processes. These interactions highlight the importance of DGKG in maintaining cellular homeostasis and its potential impact on various signaling pathways.


## References


[1. (Xu2022Screening) Man Xu, Ying-ying Guo, Dan Li, Xian-feng Cen, Hong-liang Qiu, Yu-lan Ma, Si-hui Huang, and Qi-zhu Tang. Screening of lipid metabolism-related gene diagnostic signature for patients with dilated cardiomyopathy. Frontiers in Cardiovascular Medicine, April 2022. URL: http://dx.doi.org/10.3389/fcvm.2022.853468, doi:10.3389/fcvm.2022.853468. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcvm.2022.853468)

[2. (Gravina2023Role) Teresa Gravina, Chiara Maria Teresa Boggio, Elisa Gorla, Luisa Racca, Silvia Polidoro, Sara Centonze, Daniela Ferrante, Monia Lunghi, Andrea Graziani, Davide Corà, and Gianluca Baldanzi. Role of diacylglycerol kinases in acute myeloid leukemia. Biomedicines, 11(7):1877, July 2023. URL: http://dx.doi.org/10.3390/biomedicines11071877, doi:10.3390/biomedicines11071877. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biomedicines11071877)

[3. (Schiano2022De) Concetta Schiano, Carolina Balbi, Jacopo Burrello, Antonio Ruocco, Teresa Infante, Carmela Fiorito, Stefano Panella, Lucio Barile, Ciro Mauro, Giuseppe Vassalli, and Claudio Napoli. De novo dna methylation induced by circulating extracellular vesicles from acute coronary syndrome patients. Atherosclerosis, 354:41–52, August 2022. URL: http://dx.doi.org/10.1016/j.atherosclerosis.2022.06.1026, doi:10.1016/j.atherosclerosis.2022.06.1026. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.atherosclerosis.2022.06.1026)

[4. (TaniguchiPonciano2024Longitudinal) Keiko Taniguchi-Ponciano, Silvia Hinojosa-Alvarez, Jesus Hernandez-Perez, Rocio A. Chavez-Santoscoy, Ilan Remba-Shapiro, Gerardo Guinto, Erika Magallon-Gayon, Benjamin Telles-Ramirez, Rodrigo Ponce de Leon-Conconi, Sandra Vela-Patiño, Sergio Andonegui-Elguera, Amayrani Cano-Zaragoza, Florencia Martinez-Mendoza, Jacobo Kerbel, Marco Loza-Mejia, Juan Rodrigo-Salazar, Alonso Mendez-Perez, Cristina Aguilar-Flores, Antonieta Chavez-Gonzalez, Elenka Ortiz-Reyes, Erick Gomez-Apo, Laura C. Bonifaz, Daniel Marrero-Rodriguez, and Moises Mercado. Longitudinal multiomics analysis of aggressive pituitary neuroendocrine tumors: comparing primary and recurrent tumors from the same patient, reveals genomic stability and heterogeneous transcriptomic profiles with alterations in metabolic pathways. Acta Neuropathologica Communications, August 2024. URL: http://dx.doi.org/10.1186/s40478-024-01796-x, doi:10.1186/s40478-024-01796-x. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40478-024-01796-x)